Innovent Biologics Stock Today
| IVBXF Stock | USD 4.85 0.24 4.72% |
Performance0 of 100
| Odds Of DistressOver 55
|
Innovent Biologics is trading at 4.85 as of the 1st of December 2024. This is a 4.72 percent decrease since the beginning of the trading day. The stock's lowest day price was 4.85. Innovent Biologics has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Innovent Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of December 2022 and ending today, the 1st of December 2024. Click here to learn more.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. The company has 1.53 B outstanding shares. More on Innovent Biologics
Moving together with Innovent Pink Sheet
Moving against Innovent Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Innovent Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Innovent Biologics [IVBXF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Innovent Biologics's market, we take the total number of its shares issued and multiply it by Innovent Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Innovent Biologics classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 1.53 B outstanding shares.
Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Innovent Biologics Probability Of Bankruptcy
Ownership AllocationInnovent Biologics has a total of 1.53 Billion outstanding shares. 30% of Innovent Biologics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Innovent Ownership Details
Innovent Biologics Risk Profiles
| Mean Deviation | 1.81 | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.92 | |||
| Risk Adjusted Performance | (0.02) |
Innovent Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Innovent Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Innovent Biologics Corporate Management
| Min Liu | Chief Officer | Profile | |
| Blake Salisbury | Sr Devel | Profile | |
| Eduard MD | Pres USA | Profile | |
| Yong MD | President | Profile | |
| Vivian Zhang | Chief Officer | Profile | |
| Dongming Wang | VP Quality | Profile | |
| Changshou Gao | VP CTO | Profile |
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.